Baird Reiterates a 'Neutral' on Regeneron Pharma (REGN); Kills Us to Sit on the Fence, But New Survey Shows That's the Best Place

Baird reiterates a 'Neutral' on Regeneron Pharma (NASDAQ: REGN) price target of $56.00.

Baird analyst says, "As much as we were looking for a definitive buy or sell signal from our new AMD survey detailed herein, the feedback presents both positives (Eylea awareness/anticipated use is strong) and negatives (Avastin use and price sensitivity are increasing in this space, mainly due to CATT results). Balancing this feedback with the preliminary nature of this market-read (Eylea not yet approved and not yet priced), we continue to prefer the sidelines on this name."

For more ratings news on Regeneron Pharma click here and for the rating history of Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $59.94 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• UBS Reiterates Buy Rating on HF Sinclair (DINO)